WJB001 / Wigen Biomedicine - LARVOL DELTA

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=86 | Recruiting | Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=86 | Not yet recruiting | Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd.

New P1/2 trial • Solid Tumor

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=210 | Recruiting | Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Enrolling by invitation ➔ Recruiting

Enrollment status • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=210 | Enrolling by invitation | Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Endometrial Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=210 | Not yet recruiting | Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Metastases • New P1/2 trial • Endometrial Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor